Prebiotic vs another prebiotic
- Synbiotics, prebiotics and probiotics for people with chronic kidney disease 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 24 participantsVery low
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether probiotic changes change in any GI upset or intolerance (abdominal pain/diarrhoea) compared with placebo or no treatment (very low certainty).
It is very uncertain whether probiotic changes change in any GI upset or intolerance (constipation) compared with placebo or no treatment (very low certainty).
Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).
Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).
Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty).
Risk of transient neurological symptoms with spinal lidocaine probably leads to lower presence of any TNS –lidocaine vs bupivacaine compared with other local anaesthetic (moderate certainty).
Risk of transient neurological symptoms with spinal lidocaine showed no clear difference in presence of any TNS – lidocaine vs 2‐chloroprocaine compared with other local anaesthetic (low certainty).
Risk of transient neurological symptoms with spinal lidocaine may leads to lower presence of any TNS – lidocaine vs levobupivacaine compared with other local anaesthetic (low certainty).
It is very uncertain whether risk of transient neurological symptoms with spinal lidocaine changes presence of any TNS – lidocaine vs mepivacaine compared with other local anaesthetic (very low certainty).
Risk of transient neurological symptoms with spinal lidocaine probably leads to lower presence of any TNS – lidocaine vs prilocaine compared with other local anaesthetic (moderate certainty).
Risk of transient neurological symptoms with spinal lidocaine probably leads to lower presence of any TNS – lidocaine vs procaine compared with other local anaesthetic (moderate certainty).
Risk of transient neurological symptoms with spinal lidocaine may leads to lower presence of any TNS – lidocaine vs ropivacaine compared with other local anaesthetic (low certainty).